Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · LENZ Therapeutics, Inc. (LENZ)

LENZ Therapeutics cuts staff 75% and names interim CEO as Q3 loss widens

Negative Impact 4 of 5 restructuring Written later

LENZ Therapeutics reported third-quarter 2026 product sales of $2.6 million, up about 50% from the prior quarter, but total revenue fell from $12.5 million a year earlier to $3.4 million and the net loss widened to $31.0 million. The board also approved a reorganization that cuts headcount about 75% to roughly 40 employees, with about $5 million in charges expected in the fourth quarter, and CEO Eef Schimmelpennink will be succeeded by CFO Dan Chevallard as interim CEO effective December 1, 2026.

Key points

  • Q3 2026 product sales were $2.6 million, up about 50% from Q2 2026; total revenue was $3.4 million versus $12.5 million in Q3 2025
  • Net loss was $31.0 million, or $0.99 per share, versus $16.7 million, or $0.59 per share, a year earlier
  • Reorganization reduces headcount about 75% to about 40 full-time employees, with approximately $5 million in non-recurring charges mostly in Q4 2026
  • Schimmelpennink steps down as President and CEO effective December 1, 2026; Chevallard becomes interim CEO with a $650,000 base salary

The filing

CompanyLENZ Therapeutics, Inc. (LENZ)
Form8-K, current report
Filed with the SECOct 28, 2026, 4:34 PM ET
Accession number0001815776-26-000056

Items reported: 2.02 Results of Operations2.05 Exit / Restructuring Costs5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 28, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.